Celecoxib for the prevention of nonmuscle invasive bladder cancer: results from a matched control study

Conclusions:
Our data support a clinical benefit of celecoxib and encourage future trials in which COX-2 inhibitors may be tested in selected patients with NMIBC.

Source: Therapeutic Advances in Urology - November 13, 2015 Category: Urology & Nephrology Authors: Pagliarulo, V., Ancona, P., Martines, I., Spadavecchia, R., Di Stasi, S., Alba, S., Cormio, L., Fanizza, C., Salerno, A., Carrieri, G., Pagliarulo, A. Tags: Original Research Source Type: research